Universal Cells
Taku Yoshida, currently serving as President at Universal Cells, has a wealth of experience in the field of oncology research. Previously, Yoshida held the position of Vice President at アステラス製薬, where Taku led the Immuno-Oncology division. With a background in immunology and a PhD from Kyoto University, Yoshida has also worked as a Research Fellow, Executive Director, and Scientist at various organizations such as Eisai and Dana-Farber Cancer Institute. Yoshida's expertise and leadership have been instrumental in advancing oncology research and drug discovery.
This person is not in any offices
Universal Cells
Universal Cells is a Seattle-based biotech developing, licensing and commercializing stem cell therapies that overcome immune rejection and can be used to create true off-the-shelf therapeutic products. Using the company's proprietary genome editing approach, the company engineers stem cells to prevent expression of polymorphic human leukocyteantigen (HLA) molecules, removing the cause of donor tissue rejection and creating Universal Donor Stem Cells that are compatible with every patient.